- Merck (NYSE:MRK) is ceasing improvement of two monoclonal antibody candidates it was eying as fixed-doses mixtures with its blockbuster Keytruda (pembrolizumab).
- Vibostolimab is an anti-TIGIT antibody, whereas favezelimab is an anti-LAG-3 antibody.
- The fixed-dose mixture of vibostolimab and Keytruda was